QM · rank #2 · 2026-07-22
LQDA
NASDAQ · $6.69B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +473.20% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +28.2% |
| Profit margin Net profit margin, trailing 12 months. | +7.7% |
| Market cap (USD) Size filter: > $500M required. | $6.69B |
| Anchor (recent) Close on 2026-06-22 | $75.49 |
| Anchor (far) Close on 2025-06-20 | $13.17 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Liquidia Technologies is a commercial-stage biopharma generating the majority of its revenue from YUTREPIA, an FDA-approved dry-powder inhaled treprostinil for PAH and PH-ILD competing directly against United Therapeutics' Tyvaso franchise.
Rationale
The quality_momentum signal is reinforced by three consecutive profitable quarters, 44% sequential revenue growth in Q1 2026, a positive ROE of 28%, and a 4.73 momentum score reflecting genuine fundamental acceleration rather than sentiment-only rotation.
Material risks
- 1Single-product concentration in YUTREPIA means any safety signal, formulary exclusion, or aggressive Tyvaso DPI repricing could collapse the revenue base before L606 reaches commercialization.
- 2Analyst consensus implies a meaningful sequential revenue step-down (~$110M vs. $129.9M Q1 actuals), suggesting the market anticipates near-term growth deceleration that could stall momentum if Q2 disappoints.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.